Plain-English translation of NCT06085833 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are testing a new diagnostic technology called the ARTIDIS platform that measures physical properties of breast tissue samples taken during routine biopsy. The goal is to see whether this technology can better identify what type of breast lesion you have and how aggressive it might be, compared to traditional pathology examination. Your tissue sample would be measured by this device and then returned to the standard analysis pathway.
Currently, doctors rely on microscopic examination by pathologists to determine if a breast lesion is cancer and how to treat it. This study aims to see if the new measurement technology can provide additional helpful information to improve how quickly and accurately doctors diagnose and plan treatment for breast lesions.
You likely qualify if…
You likely don't qualify if…
When you come in for your scheduled breast biopsy, an extra tissue sample will be measured using the ARTIDIS device before your samples go to the lab for routine pathology analysis—this happens the same day and doesn't delay your results. If your biopsy shows benign findings, follow-up is brief (up to 30 days). If you are diagnosed with breast cancer, the study team will collect routine follow-up information twice yearly for the first two years, then once yearly through year ten, using data already being gathered as part of your standard cancer care.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
Spain